Autres langues Syros Pharmaceuticals, Inc.

Actions

SYRS

US87184Q2066

Marché Fermé - Nasdaq Autres places de cotation 19:00:00 03/07/2024			Varia. 5j.	Varia. 1 janv.
5 ^USD	0,00 %		-12,28 %	-35,82 %

25/06	Transcript : Syros Pharmaceuticals, Inc. - Special Call
05/06	Transcript : Syros Pharmaceuticals, Inc. - Shareholder/Analyst Call

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Syros Pharmaceuticals, Inc.(NasdaqGS:SYRS) added to Russell Microcap Growth Index	01/07
Syros Pharmaceuticals, Inc.(NasdaqGS:SYRS) added to Russell 3000E Growth Index	01/07
Syros Pharmaceuticals, Inc.(NasdaqGS:SYRS) dropped from Russell Microcap Value Index	01/07
Syros Pharmaceuticals, Inc.(NasdaqGS:SYRS) dropped from Russell 3000E Value Index	01/07
Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression	13/06
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update	14/05
Syros Pharmaceuticals, Inc. Agrees to Amend Its Loan Agreement with Oxford Finance LLC	14/05
Syros Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Syros to Participate in Upcoming Investor Conferences	07/05
Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024	07/05
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	09/04
Syros Gets Fast Track Label For Tamibarotene to Treat Acute Myeloid Leukemia; Shares Rise	09/04
Syros Gets FDA Fast-Track Designation for Tamibarotene	09/04
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression	09/04
Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression	09/04
Syros Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	03/04
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/04
Health Care Rises as Upward Momentum Builds -- Health Care Roundup	28/03
Health Care Jumps as Upward Momentum Builds -- Health Care Roundup	27/03
Earnings Flash (SYRS) SYROS PHARMACEUTICALS Reports Q4 Revenue $387,000	27/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Syros Pharmaceuticals, Inc.

Actions

SYRS

US87184Q2066

Autres langues

Filtres